BIO-TECHNE Corp Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $54.01 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-09-30 was $53.60, a 28.39% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-09-30 was $74.85, a 11.25% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-09-30 was $84.34, a 10.69% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-09-30 was $94.43, a 80.40% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2026 was $54.01, a 25.67% decline from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $72.66, a 8.82% decline from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $79.69, a 15.05% decline from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $93.81, a 21.92% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $54.01 10-K · filed 2026-08-24 | |||||||
| 2026-03-31 | $53.98 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $53.93 10-Q · filed 2026-02-04 | |||||||
| 2025-09-30 | $53.60 10-Q · filed 2025-11-05 | |||||||
| 2025-06-30 | $72.66 10-K · filed 2026-08-24 | |||||||
| 2025-03-31 | $74.63 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $74.65 10-Q · filed 2026-02-04 | |||||||
| 2024-09-30 | $74.85 10-Q · filed 2025-11-05 | |||||||
| 2024-06-30 | $79.69 10-K · filed 2026-08-24 | |||||||
| 2024-03-31 | $80.07 10-Q · filed 2025-05-08 | |||||||
| 2023-12-31 | $81.49 10-Q · filed 2025-02-06 | |||||||
| 2023-09-30 | $84.34 10-Q · filed 2024-11-05 | |||||||
| 2023-06-30 | $93.81 10-K · filed 2025-08-22 | |||||||
| 2023-03-31 | $93.96 10-Q · filed 2024-05-06 | |||||||
| 2022-12-31 | $94.11 10-Q · filed 2024-02-07 | |||||||
| 2022-09-30 | $94.43 10-Q · filed 2023-11-07 | $377.72 10-Q · filed 2022-11-07 | ||||||
| 2022-06-30 | $120.15 10-K · filed 2024-08-22 | $480.59 10-K · filed 2022-08-24 | ||||||
| 2022-03-31 | $120.17 10-Q · filed 2023-05-08 | $480.67 10-Q · filed 2022-05-09 | ||||||
| 2021-12-31 | $120.87 10-Q · filed 2023-02-07 | $483.48 10-Q · filed 2022-02-07 | ||||||
| 2021-09-30 | $481.84 10-Q · filed 2022-11-07 | |||||||
| 2021-06-30 | $69.44 10-K · filed 2023-08-23 | $277.75 10-K · filed 2021-08-25 | ||||||
| 2021-03-31 | $269.64 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $267.59 10-Q · filed 2022-02-07 | |||||||
| 2020-09-30 | $267.79 10-Q · filed 2021-11-08 | |||||||
| 2020-06-30 | $190.80 10-K · filed 2022-08-24 | |||||||
| 2020-03-31 | $190.80 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | $190.73 10-Q · filed 2021-02-08 | |||||||
| 2019-09-30 | $190.39 10-Q · filed 2020-11-09 | |||||||
| 2019-06-30 | $173.89 10-K · filed 2021-08-25 | |||||||
| 2019-03-31 | $173.89 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $174.10 10-Q · filed 2020-02-06 | |||||||
| 2018-09-30 | $173.33 10-Q · filed 2019-11-06 | |||||||
| 2018-06-30 | $120.67 10-K · filed 2020-08-26 | |||||||
| 2018-03-31 | $120.34 10-Q · filed 2019-05-07 | |||||||
| 2017-12-31 | $118.97 10-Q · filed 2019-02-07 | |||||||
| 2017-09-30 | $114.60 10-Q · filed 2018-11-07 | |||||||
| 2017-06-30 | $107.42 10-K/A · filed 2019-11-06 | |||||||
| 2017-03-31 | $107.38 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $107.40 10-Q · filed 2018-02-08 | |||||||
| 2016-09-30 | $107.60 10-Q · filed 2017-11-09 | |||||||
| 2016-06-30 | $105.16 10-K · filed 2018-08-27 | |||||||
| 2016-03-31 | $105.15 10-Q · filed 2017-05-10 | |||||||
| 2015-12-31 | $105.67 10-Q · filed 2017-02-09 | |||||||
| 2015-09-30 | $106.66 10-Q · filed 2016-11-09 | |||||||
| 2015-06-30 | $93.98 10-K · filed 2017-09-07 | |||||||
| 2015-03-31 | $93.65 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | $93.68 10-Q · filed 2016-02-09 | |||||||
| 2014-09-30 | $93.95 10-Q · filed 2015-11-09 | |||||||
| 2014-06-30 | $80.88 10-K · filed 2016-08-29 | |||||||
| 2014-03-31 | $78.19 10-Q · filed 2015-05-11 | |||||||
| 2013-12-31 | $78.19 10-Q · filed 2015-02-09 | |||||||
| 2013-09-30 | $76.02 10-Q · filed 2014-11-10 | |||||||
| 2013-06-30 | $67.80 10-K · filed 2015-08-31 | |||||||
| 2012-09-30 | $74.05 10-Q · filed 2012-11-09 | |||||||
| 2012-06-30 | $71.94 10-K · filed 2014-08-29 | |||||||
| 2011-06-30 | $71.71 10-K · filed 2013-08-29 | |||||||
| 2010-06-30 | $64.71 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |